Regencell Bioscience Ltd - RGC Net earnings per share for the last 12 months

The annual EPS growth rate over the last 12 months on the GURU.Markets chart illustrates profit dynamics, where -228.30 sets the current value of the metric. Regencell Bioscience (RGC) aims to create a stable cash flow through neurosis therapy. However, the absence of commercial products deprives the company of financial momentum, while the risks of clinical trial failure and dependence on investments call the business's survival into question.

To assess an asset's fundamental stability, investors must analyze net income growth per share, where the EPS YoY TTM percentage trend serves as an indicator of the gap between market price and the business's actual yield. This metric allows for a comparison of current efficiency against historical trends, which is particularly critical for Regencell Bioscience (RGC), whose ideal production capacities are currently operating under low utilization.